Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Bank of America themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Bank of America assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research note published on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $23.00 price objective on the biopharmaceutical company’s stock. CPRX has been the topic of several other research reports. Cantor Fitzgerald boosted their […]
CenterBook Partners LP grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 20.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,577 shares of the biopharmaceutical company’s stock after acquiring an additional 2,259 shares during […]
Jackson Creek Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 68,210 shares of the biopharmaceutical company’s stock, valued at approximately $797,000. Jackson Creek Investment Advisors […]